Metabolic Alterations in a Slow-Paced Model of Pancreatic Cancer-Induced Wasting by Wyart, Elisabeth et al.
Research Article
Metabolic Alterations in a Slow-Paced Model of Pancreatic
Cancer-Induced Wasting
Elisabeth Wyart,1 Simone Reano,2 Myriam Y. Hsu,1 Dario Livio Longo ,3 Mingchuan Li ,1
Emilio Hirsch ,1 Nicoletta Filigheddu ,2 Alessandra Ghigo ,1 Chiara Riganti ,4
and Paolo Ettore Porporato 1
1Department of Molecular Biotechnology and Health Science, Molecular Biotechnology Center, University of Torino, Torino, Italy
2Department of Translational Medicine, Istituto Interuniversitario di Miologia (IIM), University of Piemonte Orientale, Novara, Italy
3Department of Molecular Biotechnology and Health Science, Molecular Imaging Center, University of Torino, Torino, Italy
4Department of Oncology, University of Torino, Torino, Italy
Correspondence should be addressed to Chiara Riganti; chiara.riganti@unito.it
and Paolo Ettore Porporato; paolo.porporato@unito.it
Received 27 October 2017; Accepted 31 December 2017; Published 26 February 2018
Academic Editor: Elisabetta Ferraro
Copyright © 2018 ElisabethWyart et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Cancer cachexia is a devastating syndrome occurring in the majority of terminally ill cancer patients. Notably, skeletal muscle
atrophy is a consistent feature affecting the quality of life and prognosis. To date, limited therapeutic options are available, and
research in the field is hampered by the lack of satisfactory models to study the complexity of wasting in cachexia-inducing
tumors, such as pancreatic cancer. Moreover, currently used in vivo models are characterized by an explosive cachexia with a
lethal wasting within few days, while pancreatic cancer patients might experience alterations long before the onset of overt
wasting. In this work, we established and characterized a slow-paced model of pancreatic cancer-induced muscle wasting that
promotes efficient muscular wasting in vitro and in vivo. Treatment with conditioned media from pancreatic cancer cells led to
the induction of atrophy in vitro, while tumor-bearing mice presented a clear reduction in muscle mass and functionality.
Intriguingly, several metabolic alterations in tumor-bearing mice were identified, paving the way for therapeutic interventions
with drugs targeting metabolism.
1. Introduction
More than half of cancer patients are suffering from a sys-
temic wasting disorder referred to as cachexia (from Greek
“bad condition”), a syndrome strongly affecting the quality
of life and prognosis in cancer patients. This syndrome is
characterized by unstoppable consumption of adipose and
skeletal muscle tissues leading to an excessive body weight
loss that cannot be fully reverted by conventional nutritional
support [1].
Cancer cachexia is a complex syndrome accounting for
multiple organ dysfunction and systemic metabolic deregula-
tions [2]. Cachectic patients experience symptoms ranging
from anorexia, elevated inflammation, and insulin resistance
to increased energy expenditure, which ultimately promote
malaise, fatigue, and impaired tolerance to chemotherapy
[3], further worsening patients’ prognosis. Besides being
associated with a poor prognosis, cachexia is estimated to
be the direct cause of one-third of cancer deaths [4]. Several
tissue dysfunctions emerge during cachexia, such as liver
steatosis, fat deposit lipolysis, intestinal dysbiosis, and, most
notably, skeletal muscle wasting, which account for the steep
decrease in quality of life, weakness, and respiratory distress
of cancer patients.
Skeletal muscle atrophy is a highly regulated process
driven by an unbalance between protein synthesis and deg-
radation. Activation of the ubiquitin-dependent proteasome
pathway (UPP) and the autophagy-lysosome system are two
important mechanisms leading to increased protein break-
down. This process is orchestrated by a set of genes called
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atrogenes, such as Atrogin-1/MAFbx or Murf1 [5]. Compel-
ling evidence shows that an impairment of mitochondrial
metabolism and an increase in mitochondrial ROS are also
strongly associated with the cachectic phenotype [6, 7].
Several tumor types, such as lung, gastrointestinal tract,
and pancreatic cancer, are emerging as strong promoters of
cancer cachexia [8]. In particular, pancreatic ductal adeno-
carcinoma (PDAC) presents a high penetrance of wasting, a
process that seems to occur even in earlier phases of tumor
transformation [9]. Despite the burden of cachexia in PDAC,
there are still limited experimental models available.
Particularly, our understanding of the biology underly-
ing cachexia is mostly based on the extensively used and
well-characterized C26 carcinoma model, in which mice
are drastically losing muscle and total body weight in a short
period [10], thus contrasting with the progressive wasting
occurring in the human pathology. It is known that the
C26 model is associated with high levels of IL6 that play a
central role in mediating muscle wasting [11], even though
other inducers are probably involved in cachexia. In order
to better characterize early stages of cachexia, we established
a model of pancreatic cancer-induced cachexia able to pro-
mote mitochondrial metabolic alterations and a progressive
wasting both in vivo and in vitro.
2. Materials and Methods
2.1. Animals. Young adult female C57BL/6J mice (9–12
weeks old) were used. All animal experiments were autho-
rized by the Italian Ministry of Health and carried out
according to the European Community guiding principles
in the care and use of animals.
2.2. Generation of a PDAC Model. KPC tumor cells were
derived from a primary culture of pancreatic tumor cells
of the genetically engineered mouse model of PDAC
(K-rasLSL.G12D/+; p53R172H/+; Pdx-Cre (KPC)).
0.7× 106 KPC cells in 200μl PBS were injected subcuta-
neously into the flank of C57bl/6J mice. Mice were sacrificed
5 weeks after injection, when tumor volume was approaching
5mm of radius.
2.3. In Vivo Assessment of Muscular Strength
2.3.1. Grip Test. An automatic grip strength meter was used
to measure the maximum forelimb grip strength of mice.
The machine measures the peak resistance force of the mouse
while the latter is pulled away from the grid of the device.
Each animal was assessed several times, and the final value
corresponds to the average of 5 repeated force measurements
in order to minimize procedure-related variability.
2.3.2. Hanging Test. A wire-hanging test was used to assess
whole-body muscle strength and endurance. The test was
performed as previously described [12]. Briefly, mice were
subjected to a 180-second hanging test on a wire, during
which “falling” and “reaching” scores were recorded. When
a mouse fell from the wire, the falling score was diminished
by 1, and when a mouse reached one of the side of the wire,
the reaching score was increased by 1. A final score was then
established using both falling and reaching scores and was
represented in the form of a Kaplan-Meier-like curve; scores
have been normalized with respect to control.
2.4. MRI. Magnetic resonance images were acquired on a 1
Tesla M2 system (Aspect, Israel) equipped with a 30mm
transmitter/receiver (TX/RX) solenoid coil to determine
body composition [13]. T1-weighted spin-echo images were
acquired with high-resolution whole-body coronal orienta-
tion (repetition time/echo time/flip angle/number excitations
[TR/TE/FA/NEX]: 400ms/9.5ms/90°/3, field of view [FOV]:
10 cm, matrix: 192× 192, number of slices: 18, slice thickness:
1.5mm, in-plane spatial resolution: 521μm, and acquisition
time: 4min). All T1-weighted images were processed by an
in-house Matlab-developed script (MATLAB R2008, The
MathWorks Inc.). The T1-weighted image histogram has
three dominating classes, background, lean mass, and fat,
so the total fat volume was isolated by segmenting the
image into three categories by using a k-means clustering
algorithm [14, 15].
2.5. Gene Expression Analysis. Gastrocnemii were harvested,
frozen in liquid nitrogen, and crushed. Total RNA was
extracted using TRIzol reagent (Invitrogen, Carlsbad, CA).
cDNA was synthesized from 1000ng of total RNA using
cDNA reverse transcription kits (Applied Biosystems, Foster
City, CA). Relative mRNA level was analyzed by real-time
PCR (ABI 7900HT FAST Real-Time PCR system, Applied
Biosystems, Foster City, CA) with TaqMan assays, using
the Universal Probe Library system (Roche Applied Science,
Penzberg, Germany). The 18S gene was used as a housekeep-
ing control. The following primers were used: FBX030
(MUSA1): F:5′-gagaagccagggtttgagc-3′ and R: 5′-tcatacagtgt
gagtgctgctg-3′, FBX032 (atrogin 1): F:5′-agtgaggaccggctac
tgtg-3′ and R: 5′-gatcaaacgcttgcgaatct-3′, TRIM63 (MuRF1):
F:5′-tgacatctacaagcaggagtgc-3′ and R: 5′-tcgtcttcgtgttccttgc-
3′, and cathepsin L F:5′-caaataagaataaatattggcttgtca-3′ and
R:5′-tttgatgtagccttccataccc-3′.
2.6. Western Blot. Protein samples from gastrocnemius were
extracted with RIPA lysis buffer (150mMNaCl, 50mM Tris-
HCl, 0.5% sodium deoxycholate, 1.0% Triton X-100, 0.1%
SDS, and 1mM EDTA) supplemented with protease and
phosphatase inhibitor cocktail (Roche). Protein concentra-
tion was determined using the BCA protein assay (Thermo
Fisher Scientific). Lysates were subjected to SDS-PAGE and
then transferred to the PVDF membrane for immunoblot-
ting analysis. The following antibodies were used: mono-
and polyubiquitin (BML-PW8805, Enzo Life Sciences,
1 : 1000), p-AMPK (2535, Cell Signaling, 1 : 1000), and β-
actin (4967, Cell Signaling, 1 : 1000).
2.7. Tissue Collection and Histology. Gastrocnemius muscle
was excised, weighted, frozen in isopentane cooled in liquid
nitrogen, and stored at −80°C. Transverse sections (7μm)
from the medial belly were cut on a cryostat and collected
on Superfrost plus glass slides. Cryosections were then proc-
essed for laminin staining. In detail, sections were fixed in 4%
paraformaldehyde (PFA) for 10min before being incubated
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with a laminin antibody (1 : 200; Dako) and visualized by an
anti-mouse IgG Alexa Fluor 488 (Thermo Fisher Scientific)
secondary antibody. Pictures of the whole slides were
acquired with the slide scanner Pannoramic Midi 1.14 (3D
Histech, Budapest, Hungary), and the cross-sectional area
(CSA) was measured automatically by ImageJ software.
2.8. Succinate Dehydrogenase Activity. Succinate dehydroge-
nase (SDH) enzymatic activity was determined on 15μm
cryosections by specific staining (Bio-Optica, Milan, Italy)
following the producer’s instructions. Briefly, the cryosec-
tions were incubated with the rehydrated SDH solution for
45min at 37°C, washed, fixed, and mounted on slides.
Images were then acquired with the slide scanner Pannora-
mic Midi 1.14.
2.9. Cell Culture and Conditioned Medium (CM) Preparation.
C2C12 cells were cultured in DMEM/10% FBS and differen-
tiated in DMEM/2% horse serum (HS) for 4 days as reported
previously [16]. KPC cells were derived from a primary cul-
ture of pancreatic tumor cells of the genetically engineered
mouse model of PDAC (K-rasLSL.G12D/+; p53R172H/+; PdxCre
mice (KPC)).
Conditioned medium (CM) was prepared as follows:
KPC cells were grown in DMEM with 10% FBS supple-
mented with 1% penicillin and streptomycin. When cells
reached full confluence, the medium was removed; cells were
washed twice with phosphate-buffered saline (PBS) and once
with serum-free DMEM. Cells were grown in serum-free
DMEM for further 24h; then, the medium was collected,
centrifuged at 4000 rpm for 10min, aliquoted, and stored at
−80°C. Atrophy on C2C12 was induced with 10% CM treat-
ment for 48 h.
2.10. Myotube Diameter Quantification. C2C12 myotubes
were treated with differentiation medium supplemented with
10% conditioned medium from KPC for 48 h. Pictures of
myotubes were taken with bright field microscopy (Zeiss),
and diameters of myotubes were measured using the software
JMicroVision as previously described [16].
2.11. ROS Measurement In Vitro. ROS production was
assessed in C2C12 myotubes by using the oxidant-
sensitive fluorescent dye 29,79-dichlorodihydrofluorescein
diacetate (H2DCFDA; Molecular Probes Inc., Eugene, OR).
Cells were incubated with 10 μM H2DCFDA in PBS for
30 minutes at 37°C under 5% CO2 atmosphere in darkness.
An excess probe was washed out with PBS. Fluorescence
was recorded at excitation and emission wavelengths of
485nm and 530nm, respectively, by a fluorescence plate
reader (Promega). Fluorescence intensity was expressed as
arbitrary units.
2.12. Mitochondrial Isolation. Mitochondrial fractions were
isolated as previously reported [17], with minor modifica-
tions. Samples were lysed in 0.5ml buffer A (50mM Tris,
100mM KCl, 5mM MgCl2, 1.8mM ATP, and 1mM EDTA
(pH7.2)), supplemented with protease inhibitor cocktail III
(Calbiochem), 1mM PMSF, and 250mMNaF. Samples were
clarified by centrifuging at 650×g for 2min at 4°C, and the
supernatant was collected and centrifuged at 13,000×g for
5min at 4°C. This supernatant was discarded, and the pellet
containing mitochondria was washed in 0.5ml buffer A and
resuspended in 0.25ml buffer B (250mM sucrose, 15mM
K2HPO4, 2mM MgCl2, 0.5mM EDTA, and 5% BSA (w/v)).
A 50μl aliquot was sonicated and used for the measurement
of protein content or Western blotting; the remaining part
was stored at −80°C.
2.13. Electron Transport Chain. The activity of complexes
I–III was measured on 25μl of nonsonicated mitochondrial
samples resuspended in 145μl buffer C (5mM KH2PO4,
5mM MgCl2, and 5% BSA (w/v)) and transferred into a 96-
well plate. Then, 100μl buffer D (25% saponin (w/v),
50mMKH2PO4, 5mMMgCl2, 5% BSA (w/v), 0.12mM cyto-
chrome c-oxidized form, and 0.2mM NaN3) was added for
5min at room temperature. The reaction was started with
0.15mM NADH and was followed for 5min, and the
absorbance was measured at 550 nm by a Synergy HT spec-
trophotometer (BioTek Instruments). Under these experi-
mental conditions, the rate of cytochrome c reduction,
expressed as nmol cyt c reduced/min/mg mitochondrial
proteins, was dependent on the activity of both complex I
and complex III [18].
2.14. Intramitochondrial ATP Levels. The amount of ATP
was measured on 20μg of mitochondrial extracts with
the ATPlite assay (PerkinElmer), according to the manu-
facturer’s instructions. Data were converted into nmol/mg
mitochondrial proteins, using a calibration curve previ-
ously set.
2.15. Intramitochondrial ROS Levels. The amount of ROS in
mitochondrial extracts was measured fluorimetrically incu-
bating mitochondrial suspension at 37°C for 10 minutes with
10μM of 5-(and-6)-chloromethyl-2,7-dichorodihydro-fluo-
rescein diacetate-acetoxymethyl ester (DCFDA-AM) and
then washed and resuspended in 0.5ml of PBS. Results were
expressed as nmol/mg mitochondrial proteins, using a cali-
bration curve previously set with a serial dilution of H2O2.
2.16. Fatty Acid β-Oxidation. Long-chain fatty acids were
measured as described by Gaster et al. [19] with minor
modifications. 100μl mitochondrial suspension was rinsed
with 100μl of 20mM HEPES, containing 0.24mM fatty
acid-free BSA, 0.5mM L-carnitine, and 2μCi [1-14C]palmitic
acid (3.3mCi/mmol, PerkinElmer). Samples were incubated
at 37°C for 1 h; then, 100μl of 1 : 1 phenylethylamine
(100mM)/methanol solution (v/v) was added. After one
hour at room temperature, the reaction was stopped by
adding 100μl of 0.8N HClO4. Samples were centrifuged
at 13,000×g for 10min. Both the precipitates containing
14C acid-soluble metabolites (ASM) and the supernatants
containing 14CO2 derived from oxidation (used as an internal
control and expected to be less than 10% of ASM) were
counted by liquid scintillation. Results are expressed as
nmol/min/mg cellular proteins.
2.17. Statistics. Statistical significance was evaluated with
one-way or two-way analysis of variance (ANOVA) for
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multiple groups, followed by a post hoc test as defined in the
figure legends. Student’s unpaired t-test was used to compare
two groups. All error bars indicate SEM. Significance was
established as P < 0 05. Data have been obtained from multi-
ple independent experiments for an in vitro assay and from at
least 4 mice for in vivo experiments. All the analyses were
performed with the software PRISM5 (GraphPad Software).
3. Results
3.1. Establishment of a Slow-Paced Cancer-Induced Muscle
Wasting Model. PDAC is known to induce muscle wasting
with high penetrance [3]. Since cancer cachexia is a com-
plex syndrome involving various pathological processes
promoting wasting, such as anorexia and chronic inflam-
mation, it is difficult to assess the direct contribution from
the tumor. Therefore, we decided to assess the direct role
of cancer cells in skeletal muscle atrophy via an in vitro
model of atrophy, thus excluding other systemic con-
founding atrophic factors, hypothesizing that, in this type
of cancer, atrophy can be mediated directly by tumor cell-
secreted factors.
To this aim, we took advantage of KPC cells, a stable
cell line derived from spontaneous primary tumor arising
in C57BL/6 KRASG12D P53R172HPdx-Cre+/+ (KPC) mouse
[20], a genetically modified mouse model known to develop
spontaneous wasting [9]. Similar to other cancer models
[21], in our experimental conditions, KPC cells were able to
directly promote muscle atrophy in vitro. Treatment of
C2C12-derived myotubes with 10% KPC cell-conditioned
media induced a consistent reduction in myotube thickness,
similar to that elicited by dexamethasone, used as a positive
control of atrophy induction (Figure 1(a)). A reduction in
fiber thickness was associated with higher ROS generation
(Figure 1(b)). A recent report from Michaelis et al. [20]
showed that a subcutaneous injection of 5 million of these
cells consistently promotes anorexia, hormonal dysfunc-
tions, and lethal cachexia in 2 weeks. In order to establish
a progressive model of wasting, we subcutaneously injected
0.7 million of KPC cells, which is the minimal amount able
to consistently induce tumor growth without exacerbating
factors such as excessive tumor burden and anorexia.
Indeed, 5 weeks after KPC cell injection, neither food
intake alteration (Figure 1(c)) nor macroscopic features of
wasting were observed, despite a nonsignificant decreasing
trend in body weight (Figure 1(d)). Tumor weight at the
end of the experiment was approximatively 0.6 grams
(Figure 1(e)), while in the other work, weight was between
1 and 2 grams [20].
Remarkably, despite the absence of overt signs of
cachexia, skeletal muscle functionality, checked by rotarod
evaluation twice a week (not shown), was drastically affected,
but only at week 5, the week of the sacrifice. Accordingly,
tumor-bearing mice showed reduced muscle performance,
as assessed by the hanging-wire test [12] (Figure 1(f)),
suggesting muscle deterioration in tumor-bearing animals.
Along with reduced performance in stamina-related assays,
mice displayed as well a reduction in grip strength,
indicating also that the maximal force developed was
reduced (Figure 1(g)).
Coherently with the decrease in muscle functionality, 5
weeks after KPC injection, mice presented a consistent loss
of gastrocnemius mass of roughly 20% (Figure 2(a)). The
decrease was related to a reduction in average fiber size as
detailed by histological analysis (Figures 2(b)–2(d)). Coher-
ently, analysis of fiber cross-sectional area (CSA) distribution
highlighted a shift towards smaller areas (Figure 2(e)). A
reduction in muscle mass was not associated with transcrip-
tional regulation of atrogenes Atrogin1, Musa, and Murf1
and of cathepsin L (Figures 2(f)–2(i)), nor with altered
expression of ATG7, BECLIN1, and LC3 in gastrocnemii
(not shown). Nevertheless, muscle protein lysates presented
increased protein ubiquitination (Figure 2(j)), indicative of
an activation of the UPP. Along with increased protein ubi-
quitination, we identified higher AMPK phosphorylation,
in line with the emerging role of AMPK as a functional player
in cancer cachexia [22].
3.2. Mice Undergoing Muscle Dysfunction Present Altered
Lipid Metabolism. Given the importance of energy metabo-
lism in regulating skeletal muscle mass and functionality
[23, 24], we investigated potential alterations of mitochon-
drial metabolism in the skeletal muscle of KPC-bearing mice.
To this aim, we assessed basal complex II activity in gastroc-
nemii by performing the succinate dehydrogenase (SDH)
activity assay. Intriguingly, gastrocnemius sections from
KPC-bearing animals presented increased complex II activ-
ity, as evidenced by the increased concentration of blue tetra-
zolium salt (Figure 3(a)). However, this increased activity was
not coupled with elevated flux through the electron transport
chain (ETC). Indeed, ETC, as measured by cytochrome c
reduction rate in uncoupled mitochondria, was similar in
the two groups (Figure 3(b)).
While SDH activity supports ETC, it is also part of the tri-
carboxylic acid (TCA) cycle and it is linked to fatty acid oxi-
dation, allowing ketone bodies generated by acetyl coenzyme
A due to excessive fatty acid oxidation to enter the TCA.
To clarify whether the increased SDH activity was
indicative of increased fatty acid oxidation, we measured
this metabolic pathway in isolated mitochondria from the
gastrocnemius of either control or KPC-bearing mice and
we observed a significant increase in fatty acid oxidation
in muscles of tumor-bearing mice (Figure 3(c)), consistent
with the increase in complex II activity.
In order to identify if the altered intramuscular lipid
oxidation was correlated with a systemic dysregulation dur-
ing this precachectic process, we performed T1-weighted
magnetic resonance imaging (MRI). Intriguingly, 4 weeks
post-KPC injection (one week before sacrifice), precachectic
mice presented reduced bright hyperintensity regions,
indicative of reduced fat deposits (Figures 3(d) and 3(e)).
Coherently, at the time of sacrifice, KPC-bearing mice
presented a significant reduction in inguinal fat tissue mass
(Figure 3(f)). Therefore, we speculated that the reduced fat
content might be related to increased fatty acid oxidation, a
feature previously associated with cancer cachexia [23] in
other tumor types.
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High SDH activity [25, 26] and excessive fatty acid
oxidation might lead to ROS accumulation [27], ultimately
promoting mitochondrial dysfunction [28] and fiber dam-
age. Hence, we investigated the impact of tumor growth
on mitochondrial ROS and energetic balance. Mitochon-
dria extracted from KPC-bearing animals had indeed
increased ROS (Figure 3(g)), coupled with reduced ATP
(Figure 3(h)), suggesting that the increased fatty acid oxi-
dation may have a detrimental rather than beneficial effect
on mitochondria.
4. Discussion
Pancreatic cancer is a pathology with dismal prognosis
associated with a stark decrease in quality of life, mostly
because of cachexia development [29, 30]. While cachexia
is considered the last step of cancer progression, it is
important in PDAC to model the earliest steps of the dis-
ease (i.e., precachexia). Indeed, Mayers et al. [9] found that
spontaneous PDAC mouse model presents an increased
release of amino acids from the skeletal muscle months
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Figure 1: Characterization of an in vitro and in vivo model of cancer-associated atrophy. C2C12 myotubes treated for 48 h with 10%
conditioned medium (CM) from KPC cells. Dexamethasone (DEXA) was used as a positive control of atrophy induction. Pictures were
acquired at the brightfield microscope and (a) diameters were measured. (b) Increased ROS production in C2C12 myotubes treated with
CM from KPC using oxidant-sensitive fluorescent dye H2DCFDA. (c) No difference in food intake in tumor-bearing versus control mice
at the end of the experiment. (d) No significant weight loss in KPC tumor-bearing versus control mice. (e) Average tumor weight (min
max box plot). Upon tumor growth at the end stage, mice presented reduced muscular resistance as evidenced by (f) performance at the
hanging test (reach/fall assay) and (g) maximal strength as performed by the grip test of the upper limbs. All experiments have been
performed with N≥ 4 mice per group. All data are shown as means± SEM; n.s. = nonsignificant; ∗P < 0 05; ∗∗∗P < 0 001; one-way
ANOVA with Bonferroni correction for (a), two-way ANOVA with Dunnett’s multiple comparison test for (e), and Student’s t-test for
(b), (c), (d), (f), and (g).
5Oxidative Medicine and Cellular Longevity
050
100
G
as
tro
cn
em
iu
s
no
rm
al
iz
ed
 w
ei
gh
t (
%
)
Control KPC
⁎⁎
(a)
Ctr KPC
(b)
KP
C
C
on
tro
l
(c)
0
500
1000
1500
2000
2500
⁎
CS
A
 (휇
m
2 )
Control KPC
(d)
0
5
10
15
Control
KPC-injected mice
CSA area (휇m2)
Fr
eq
ue
nc
y 
(%
)
20
0
40
0
60
0
80
0
10
00
12
00
14
00
16
00
18
00
20
00
22
00
24
00
26
00
28
00
30
00
32
00
34
00
36
00
38
00
40
00
42
00
44
00
46
00
48
00
50
00
(e)
Control KPC
1.5
n.s.
Murf
1.0
Re
la
tiv
e q
ua
nt
ity
0.5
0.0
(f)
Control KPC
Musa 1
n.s.
1.5
1.0
Re
la
tiv
e q
ua
nt
ity
0.5
0.0
(g)
Control KPC
Atrogin 1
n.s.
1.5
1.0
Re
la
tiv
e q
ua
nt
ity
0.5
0.0
(h)
Figure 2: Continued.
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before the development of cachexia, which is consistent
with the data from PDAC patients [9]. These data advocate
for the importance of defining alterations in skeletal muscle
occurring in the early phases of disease, before the estab-
lishment of overt cachexia.
To this aim, we modified the cancer cachexia model
described by Michaelis et al. to reproducibly induce
cachexia with KPC cells [20]. Since KPC-bearing male mice
present hormonal dysfunctions, we performed the study in
female mice, although these animals are characterized by a
moderate degree of wasting. While Michaelis and coworkers
modeled cachexia by injecting up to 5× 106 cells per mouse,
thus promoting anorexia and subsequent animal death
starting from 11–14 days, we injected only 0.7× 106 cells
(the minimal amount necessary to consistently promote
tumor growth) in order to promote a slower tumor growth,
thus allowing the characterization of precachectic events.
This reduced cell number resulted in barely palpable tumors
at 2 weeks after injection (the time point where mice from
Michaelis et al. already started to die of cachexia). More-
over, in contrast to the effects reported with the injection
of higher amount of KPC cells, smaller tumor mass (up to
75% reduction) and no effect on heart weight were observed
(data not shown).
Despite the moderate degree of wasting, mice pre-
sented reduced muscle function and strength. In order
to detect alterations in muscle morphology occurring at
early phases of wasting, we sacrificed the mice at the first
sign of decreased performance. At necropsy, mice pre-
sented a statistically significant reduction in gastrocnemius
weight and fat deposit, but no signs of anorexia, excluding
the involvement of food intake in the skeletal muscle mass
reduction. Intriguingly, we found only a trend towards
decreased body weight, similar to the findings of Brown
and colleagues [7]. Of note, it is known that many tumors
hijack organ function, especially the liver and spleen [3],
by inducing increased organ size, which might counterbal-
ance the drop in muscle and fat in the first phases. Mus-
cle from tumor-bearing mice did not present any major
transcriptional regulation of the investigated atrogenes.
However, we identified increased levels of AMPKT172
phosphorylation, indicative of ongoing energy stress, and
protein ubiquitination indicating that the alterations pres-
ent in muscle were mediated by a different pathway, that
is, alternative ubiquitin ligase, a regulation at protein level,
or alterations in protein deubiquitinases.
As previously shown in clear cell kidney cancer, muscle
undergoing wasting is causally linked to increased fatty acid
oxidation [23, 31], potentially raising noxious ROS genera-
tion in the mitochondria. Noteworthy, also in our model,
the significant drop in lipid was coupled with an increased
fatty acid utilization and mitochondrial ROS generation,
indicating a potential source of oxidative stress causing
reduced muscular function and degeneration. Intriguingly,
we identified an increased activity of SDH, uncoupled with
increased ETC flux. Moreover, ATP content was decreased,
suggesting a profound mitochondrial alteration. This obser-
vation further supports the concept that mitochondrial alter-
ations occur at the early phases of cachexia. While SDH does
not contribute to increasing mitochondrial energy metabo-
lism in cachectic muscles, it promotes the metabolism of
ketone body derivatives that are produced in conditions
of high fatty acid oxidation, that is, in the same metabolic
conditions of KPC-bearing muscles. Redox cycles occurring
at complex I and complex III of the ETC are generally con-
sidered the key sources of ROS within mitochondria. How-
ever, also, the SDH complex has been recognized as an
important source of intramitochondrial ROS [25]. Taken
together, our findings suggest that muscles consume fatty
acids, forcing SDH activity in early cachexia. The final
result is an energetic catastrophe that may severely impair
muscle physiological performance.
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Figure 2: KPC cell injection promotes skeletal muscle atrophy. (a) Gastrocnemius weight normalized on tibial length. (b) H&E representative
pictures of muscle sections from control and KPC-injected mice. (c–e) Gastrocnemius myofiber membranes were stained for laminin,
pictures of the whole muscle section were acquired, and the cross-sectional area (CSA) was measured (c). (d) Frequency histogram
showing distribution of myofiber CSA in control and KPC-bearing mice. N = 4. (e) Representative pictures of laminin staining for CSA
analysis in control and KPC-bearing mice. (f–i) KPC injection does not upregulate atrogene expression. N ≥ 4. (j) Increased protein
ubiquitination and AMPK (T172) phosphorylation in mice bearing tumor; blot representative of three independent experiments. All data
are shown as means± SEM. Statistical analyses were conducted using two-tailed t-test. n.s. = nonsignificant.
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Interestingly, in vitro myotubes did not show increased
fatty acid oxidation during atrophy (not shown), in line with
the fact that culture and differentiation media contain lim-
ited amount of fatty acids. However, C2C12 cells treated
with the medium of pancreatic cancer cells displayed the
same alterations observed in cachectic muscles, notably high
ROS levels and AMPK phosphorylation (not shown), sug-
gesting that common metabolic alterations in mitochondrial
metabolism occur in the early phase of cachexia both in vitro
and in vivo.
In conclusion, we report a novel model of precachexia
causing a drastic reduction in muscle function and an ini-
tial reduction in skeletal muscle mass. Interestingly, the
onset of increased fatty acid oxidation and mitochondrial
ROS generation occurs before the emergence of muscle
mass reduction. Further test inhibiting fatty acid oxidation
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Figure 3: Metabolic dysregulation of skeletal muscle in KPC-bearing mice. (a) Representative images for succinate dehydrogenase (SDH)
activity stain. (b) Gastrocnemius mitochondria were isolated, and ETC activity from complex I to complex III was assessed by evaluating
cytochrome c reduction. (c) 14C-labeled palmitate was used as a substrate to measure lipid beta-oxidation in isolated mitochondria of
gastrocnemius from control and KPC-bearing mice. (d) Representative T1-weighted MR images (brightest regions in T1-weighted MR
images correspond to adipose regions) and (e) in vivo measurement of adipose tissue using MR images in the control group versus KPC-
bearing mice. (f) Weight of inguinal fat normalized on tibial length for control versus KPC-bearing mice. (g) Gastrocnemius mitochondria
were isolated, and ATP level was assessed using the ATPlite kit (PerkinElmer, USA). (h) ROS measurement in isolated mitochondria from
gastrocnemius using H2DCFDA. N≥ 4. All data are shown as means± SEM. Statistical analysis was conducted using two-tailed t-test.
n.s. = nonsignificant; ∗P < 0 05; ∗∗P < 0 01.
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or mitochondrial ROS generation will be instrumental in
understanding the relative contribution of such pathways
to the pathogenesis of cachexia, as well as in the identifica-
tion of the factors secreted by PDAC cells causing muscle
atrophy, both in vitro and in vivo.
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